Literature DB >> 3113515

Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor.

J Mimuro, R R Schleef, D J Loskutoff.   

Abstract

The extracellular matrix (ECM) of cultured bovine aortic endothelial cells (BAEs) was analyzed by immunoblotting and reverse fibrin autography and shown to contain type 1 plasminogen activator inhibitor (PAI-1). Most PAI-1 in the ECM formed complexes with exogenously added tissue-type plasminogen activator (tPA), demonstrating that this PAI-1 was functionally active. The resulting tPA/PAI-1 complexes were recovered in the reaction solution, indicating that the PAI-1 in such complexes no longer bound to ECM. The PAI-1 could not be removed by incubating ECM in high salt (2 mol/L NaCl), sugars (1 mol/L galactose, 1 mol/L mannose), glycosaminoglycans (10 mmol/L heparin, 10 mmol/L dermatan sulfate), or epsilon-aminocaproic acid (0.1 mol/L). However, PAI-1 could be extracted from ECM by treatment with either arginine (0.5 mol/L) or potassium thiocyanate (2 mol/L), or by incubation under acidic conditions (pH 2.5). ECM depleted of PAI-1 by acid extraction was able to bind both the active and latent forms of PAI-1. In this instance, most of the bound PAI-1 did not form complexes with tPA, indicating that the latent form was not activated as a consequence of binding to ECM. Although the PAI-1 activity in conditioned medium decayed with a half-life (t 1/2) of less than 3 hours, the t 1/2 of ECM-associated PAI-1 was greater than 24 hours. These data suggest that PAI-1 is produced by cultured BAEs in an active form and is then either released into the medium where it is rapidly inactivated or into the subendothelium where it binds to ECM. The specific binding of PAI-1 to ECM protects it from this inactivation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3113515

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Transforming growth factor-ßs as modulators of pericellular proteolytic events.

Authors:  J Keski-Oja; J Lohi; M Laiho
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

2.  Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy?

Authors:  D J Buttle; H Bramwell; A P Hollander
Journal:  Clin Mol Pathol       Date:  1995-08

3.  Impact of plasminogen on an in vitro wound healing model based on a perfusion cell culture system.

Authors:  Moyuru Hayashi; Yuichi Matsuzaki; Motoyuki Shimonaka
Journal:  Mol Cell Biochem       Date:  2008-11-01       Impact factor: 3.396

Review 4.  The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.

Authors:  J E Testa; J P Quigley
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

5.  Immunohistochemical localization of plasminogen activator inhibitor-1 in human coronary atherosclerotic lesions involved in acute myocardial infarction.

Authors:  K Yorimitsu; T Saito; T Toyozaki; T Ishide; N Ohnuma; Y Inagaki
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

6.  Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy.

Authors:  J Schneiderman; M Sawdey; H Craig; T Thinnes; G Bordin; D J Loskutoff
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

7.  A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

Authors:  Yufeng Huang; Masashi Haraguchi; Daniel A Lawrence; Wayne A Border; Ling Yu; Nancy A Noble
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis.

Authors:  E Bacharach; A Itin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

9.  Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.

Authors:  F Samad; K Yamamoto; D J Loskutoff
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

10.  Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

Authors:  M S Sawdey; D J Loskutoff
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.